Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > The original post re the chair woman is removed
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(200)
•••
Comment by palinc2000on Mar 13, 2024 9:31am
104 Views
Post# 35930183

RE:The original post re the chair woman is removed

RE:The original post re the chair woman is removed

I assume that Dawn had your post removed!!!
Your post was not  that agressive at all.She has problem facing the truth ....I votedf against her and all other BOD mmbers xcept Levesque Arena and Trudeau I think
Dawn should be ashamed of getting paid so much for so many bad decidions
I suspect she is the one protecting  Dubuc the wiorst CFO I have ever seen


scarlet1967 wrote: Maybe I used aggressive language but it was my opinion about how I see things. Thereatetechnologies I also have posted many times positive reviews which also were my opinions. Stockhouse is supposed to be a forum where everyone can share their opinions. Good bad or ugly!!

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities